- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04608136
Egg Yolk and Underlying Metabolisms on Modifying HDL Levels in Individuals With Metabolic Syndrome
7. april 2022 opdateret af: Mahidol University
Egg Yolk and Underlying Metabolisms on Modifying HDL Levels and Associated Genetics in Individuals With Metabolic Syndrome
This research compare the effects of low carbohydrate intake and consumption of 3 eggs per day, and low energy diet on diabetes control and biomarkers of CVD in obese people.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This research study examines the effects of changes in weight, metabolism of glucose and cholesterol in the blood through diet and behavior modification.
The main objective of this study was to compare the effects of low carbohydrate intake and consumption of 3 eggs per day, and low energy diet on diabetes control and biomarkers of CVD in obese people.
In addition, HDL quantity and size as well as HDL function was compared between the group who ate the whole egg and the group who did not eat the yolk.
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
76
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Bangkok
-
Bangkok Noi, Bangkok, Thailand, 10700
- Faculty of Medicine Siriraj Hospital, Mahidol University
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 60 år (Voksen)
Tager imod sunde frivillige
Ja
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- weight stable > 3 months (changing < 5%)
- three or more of the following five criteria are met 2.1 waist circumference ≥ 90 cm (men) or ≥ 80 cm (women) 2.2 fasting blood sugar ≥ 100 mg/dl 2.3 fasting triglyceride (TG) level ≥ 150 mg/dl 2.4 fasting high-density lipoprotein (HDL) cholesterol level ≤ 40 mg/dl (men) or ≤ 50 mg/dl (women) 2.5 blood pressure over 130/85 mmHg
- can consume food that provided in project
- healthy
Exclusion Criteria:
- consume drugs i.e. weight loss drugs, herbal pills, asthma drugs, steroid drugs, thyroid drugs, insulin injections, SGLT1 inhibitors drugs, SGLT2 inhibitors drugs, sulfonylurea drugs, blood lipid-lowering drugs
- people who exercise vigorously (> 150 minutes per week)
- people who are or have weight loss by consuming less than 30% of carbohydrates, or are losing weight by other methods or who have eaten a specific diet as prescribed by a doctor within the past 6 months
- people who drink alcohol more than once a week
- people who had a LDL level within 6 months > 190 mg/dl
- fasting blood glucose levels > 250 mg/dl and using diabetes drugs other than metformin
- people with heart disease, type 1 diabetes, renal impairment > level 3A
- history of cancer, lung disease, gastrointestinal disease
- people who smoke, people with eating disorder, people who have received psychiatric drugs
- become a volunteer in a research project that is conducting a study related to food consumption
- people who are unable to keep up with the treatment or are expected to be absent in this area for the next 4 months
- pregnancy or breastfeeding
- egg allergy
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Yolk ketogenic diet
consume carbohydrate < 10% and 3 whole eggs supplement per day in 12 weeks
|
Volunteers will be instructed on dietary recommendation throughout the research program to achieve a stable daily energy intake.
|
|
Eksperimentel: White ketogenic diet
consume carbohydrate < 10% and 6 white eggs supplement per day in 12 weeks
|
Volunteers will be instructed on dietary recommendation throughout the research program to achieve a stable daily energy intake.
|
|
Aktiv komparator: Control group
decrease consumption of diet from typical (decreased energy 20%) but consume carbohydrate in normal level
|
Volunteers will be instructed on dietary recommendation throughout the research program to achieve a stable daily energy intake.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Changes in weight following dietary intervention
Tidsramme: Baseline and after 12 weeks
|
weight (kg) analysis
|
Baseline and after 12 weeks
|
|
Changes in body mass index following dietary intervention
Tidsramme: Baseline and after 12 weeks
|
body mass index (kg/m^2) analysis
|
Baseline and after 12 weeks
|
|
Changes in waist circumference following dietary intervention
Tidsramme: Baseline and after 12 weeks
|
waist circumference (cm) analysis
|
Baseline and after 12 weeks
|
|
Changes in lipid profiles concentration following dietary intervention
Tidsramme: Baseline and after 12 weeks
|
Triglycerides (mg/dl), Cholesterol (mg/dl), HDL-cholesterol (mg/dl) and LDL-cholesterol (mg/dl) concentration analysis
|
Baseline and after 12 weeks
|
|
Changes in blood glucose and insulin concentration following dietary intervention
Tidsramme: Baseline and after 12 weeks
|
HbA1C (%), glucose (mg/dl) and insulin (mg/dl) concentration analysis
|
Baseline and after 12 weeks
|
|
Changes in betahydroxybutirate concentration following dietary intervention
Tidsramme: Baseline and after 12 weeks
|
betahydroxybutirate (mmol/L) concentration analysis
|
Baseline and after 12 weeks
|
|
Changes in electrolytes concentration following dietary intervention
Tidsramme: Baseline and after 12 weeks
|
Na+ (mg/dl), K+ (mg/dl), Cl- (mg/dl) and HCO3- (mg/dl) concentration analysis
|
Baseline and after 12 weeks
|
|
Changes in physical activity
Tidsramme: Baseline and after 12 weeks
|
physical activity (MET-minutes/week) collect data by using questionnaires
|
Baseline and after 12 weeks
|
|
Change from baseline Glycemia at 180 minutes
Tidsramme: Minutes after intake of 75 g glucose: 0, 30, 60, 90, 120, 180
|
glucose (mg/dl)
|
Minutes after intake of 75 g glucose: 0, 30, 60, 90, 120, 180
|
|
Change from baseline Insulin at 180 minutes
Tidsramme: Minutes after intake of 75 g glucose: 0, 30, 60, 90, 120, 180
|
insulin (μU/ml)
|
Minutes after intake of 75 g glucose: 0, 30, 60, 90, 120, 180
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Changes in blood pressure
Tidsramme: Baseline and after 12 weeks
|
systolic and diastolic blood pressure (mmHg)
|
Baseline and after 12 weeks
|
|
Changes in fasting leptin levels
Tidsramme: Baseline and after 12 weeks
|
leptin (mg/dl) concentration analysis
|
Baseline and after 12 weeks
|
|
Changes in energy intake following dietary intervention
Tidsramme: Baseline and after 12 weeks
|
energy (kcal)
|
Baseline and after 12 weeks
|
|
Changes in carbohydrate following dietary intervention
Tidsramme: Baseline and after 12 weeks
|
carbohydrate (g)
|
Baseline and after 12 weeks
|
|
Changes in protein intake following dietary intervention
Tidsramme: Baseline and after 12 weeks
|
protein (g)
|
Baseline and after 12 weeks
|
|
Changes in fat intake following dietary intervention
Tidsramme: Baseline and after 12 weeks
|
fat (g)
|
Baseline and after 12 weeks
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Samarbejdspartnere
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
21. september 2020
Primær færdiggørelse (Faktiske)
31. maj 2021
Studieafslutning (Faktiske)
31. december 2021
Datoer for studieregistrering
Først indsendt
21. september 2020
Først indsendt, der opfyldte QC-kriterier
28. oktober 2020
Først opslået (Faktiske)
29. oktober 2020
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
8. april 2022
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
7. april 2022
Sidst verificeret
1. april 2022
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- MU-CIRB 2019/255.0310
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Metabolisk syndrom
-
Consorcio Centro de Investigación Biomédica en...Hospital General Universitario Gregorio Marañon; Universidad Complutense... og andre samarbejdspartnereIkke rekrutterer endnuLeverfibrose/NASH | MASH - Metabolic Dysfunction-Associated Steatohepatitis | MASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseSpanien
-
Rivus Pharmaceuticals, Inc.RekrutteringMASH - Metabolic Dysfunction-Associated SteatohepatitisForenede Stater
-
Madrigal Pharmaceuticals, Inc.RekrutteringMASH - Metabolic Dysfunction-Associated SteatohepatitisForenede Stater
-
Shanghai East HospitalRekrutteringMASH - Metabolic Dysfunction-Associated SteatohepatitisKina
-
Southern California Institute for Research and...Ikke rekrutterer endnuMASH - Metabolic Dysfunction-Associated Steatohepatitis
-
Nabiqasim Industries (Pvt) LtdRekrutteringMASH - Metabolic Dysfunction-Associated SteatohepatitisPakistan
-
Fondazione Policlinico Universitario Agostino Gemelli...RekrutteringMASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseItalien
-
Tangram Therapeutics PlcRekrutteringSunde deltagere | MASH - Metabolic Dysfunction-Associated SteatohepatitisDet Forenede Kongerige
-
University of Campania Luigi VanvitelliAfsluttetMASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseItalien
-
University Hospital, Basel, SwitzerlandIkke rekrutterer endnuKardiovaskulær-Kidney-metabolsk syndrom | Cradiovascular-Kidney-Liver-Metabolic (CKLM) syndromSchweiz
Kliniske forsøg med Diet intervention
-
University of California, Los AngelesIkke rekrutterer endnuIgA nefropati (IgAN)Forenede Stater
-
Hospital de Clinicas de Porto AlegreAfsluttet
-
Mondelēz International, Inc.KGK Science Inc.Afsluttet
-
Chinese University of Hong KongRekrutteringThoracale neoplasmerHong Kong
-
University of Alabama at BirminghamNational Multiple Sclerosis SocietyAfsluttetMultipel scleroseForenede Stater
-
Mondelēz International, Inc.KGK Science Inc.Afsluttet
-
Vastra Gotaland RegionGöteborg UniversityTilmelding efter invitation
-
Ondokuz Mayıs UniversityTilmelding efter invitationErnæringsvurdering | Ernæringsintervention | PCOS- Polycystisk ovariesyndromTyrkiet (Türkiye)
-
Biruni UniversityAfsluttet